Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Osimertinib has become standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients whereas drug resistance remains inevitable. Now we recognize that the inter...

Source: BMC Medicine - April 24, 2024 Category: Internal Medicine Authors: Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li and Caicun Zhou Tags: Research article Source Type: research